We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

Novartis in Focus. Based in Basel, Novartis (NVS) is in the Medical sector, and so far this year, shares have seen a price change of 21.05%. Currently paying a dividend of $2.6 per share, ...

Failures at Novartis have prompted U.K. | Failures at Novartis have prompted the U.K. marketing watchdog to warn that “companies should be on high alert” when working with third parties to ...

Novartis argues that it needs the court to issue its decision on the ‘918 patent case quickly because MSN has indicated it’s willing to launch at risk as soon as it has approval and isn’t ...

Novartis in Focus. Based in Basel, Novartis (NVS) is in the Medical sector, and so far this year, shares have seen a price change of 21.05%. Currently paying a dividend of $2.6 per share, ...

Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically ...

She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage ...

In 2023, Art Basel redesigned the layout of its Miami Beach expo around five interior plazas, partly to re-engineer foot-traffic patterns. In 2024, ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

While the execs with Lilly and Novartis appeared curious but cautious about PD-(L)1xVEGF bispecifics, it’s worth noting that biopharma companies often present a degree of impartiality on hot ...